首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study.
【24h】

Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study.

机译:血液透析患者骨重塑和冠状动脉钙化变化的关联:一项前瞻性研究。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Vascular calcification is common and constitutes a prognostic marker of mortality in the hemodialysis population. Derangements of mineral metabolism may influence its development. The aim of this study is to prospectively evaluate the association between bone remodeling disorders and progression of coronary artery calcification (CAC) in hemodialysis patients. STUDY DESIGN: Cohort study nested within a randomized controlled trial. SETTING & PARTICIPANTS: 64 stable hemodialysis patients. PREDICTOR: Bone-related laboratory parameters and bone histomorphometric characteristics at baseline and after 1 year of follow-up. OUTCOMES: Progression of CAC assessed by means of coronary multislice tomography at baseline and after 1 year of follow-up. Baseline calcification score of 30 Agatston units or greater was defined as calcification. Change in calcification score of 15% or greater was defined as progression. RESULTS: Of 64 patients, 38 (60%) of the patients had CAC and 26 (40%) did not [corrected].Participants without CAC at baseline were younger (P < 0.001), mainly men (P = 0.03) and nonwhite (P = 0.003), and had lower serum osteoprotegerin levels (P = 0.003) and higher trabecular bone volume (P = 0.001). Age (P = 0.003; beta coefficient = 1.107; 95% confidence interval [CI], 1.036 to 1.183) and trabecular bone volume (P = 0.006; beta coefficient = 0.828; 95% CI, 0.723 to 0.948) were predictors for CAC development. Of 38 participants who had calcification at baseline, 26 (68%) had CAC progression in 1 year. Progressors had lower bone-specific alkaline phosphatase (P = 0.03) and deoxypyridinoline levels (P = 0.02) on follow-up, and low turnover was mainly diagnosed at the 12-month bone biopsy (P = 0.04). Low-turnover bone status at the 12-month bone biopsy was the only independent predictor for CAC progression (P = 0.04; beta coefficient = 4.5; 95% CI, 1.04 to 19.39). According to bone histological examination, nonprogressors with initially high turnover (n = 5) subsequently had decreased bone formation rate (P = 0.03), and those initially with low turnover (n = 7) subsequently had increased bone formation rate (P = 0.003) and osteoid volume (P = 0.001). LIMITATIONS: Relatively small population, absence of patients with severe hyperparathyroidism, short observational period. CONCLUSIONS: Lower trabecular bone volume was associated with CAC development, whereas improvement in bone turnover was associated with lower CAC progression in patients with high- and low-turnover bone disorders. Because CAC is implicated in cardiovascular mortality, bone derangements may constitute a modifiable mortality risk factor in hemodialysis patients.
机译:背景:血管钙化是常见的,并且构成血液透析人群死亡率的预后标志。矿物质代谢紊乱可能会影响其发育。这项研究的目的是前瞻性评估血液透析患者的骨重塑障碍与冠状动脉钙化(CAC)进展之间的关联。研究设计:队列研究嵌套在随机对照试验中。场所和参与者:64名稳定的血液透析患者。预测:基线和随访1年后与骨有关的实验室参数和骨组织形态计量学特征。结果:在基线和随访1年后,通过冠状动脉多层层析成像评估了CAC的进展。基线钙化得分为30 Agatston单位或更高,定义为钙化。钙化分数变化为15%或更高被定义为进展。结果:在64例患者中,有38例(60%)患有CAC,而26例(40%)没有[校正]。基线时无CAC的参与者较年轻(P <0.001),主要是男性(P = 0.03)和非白人。 (P = 0.003),并具有较低的血清骨保护素水平(P = 0.003)和较高的小梁骨体积(P = 0.001)。年龄(P = 0.003;β系数= 1.107; 95%置信区间[CI],1.036至1.183)和小梁骨体积(P = 0.006;β系数= 0.828; 95%CI,0.723至0.948)是CAC发展的预测因素。在基线时有钙化的38位参与者中,有26位(68%)在1年内发生了CAC进展。进展期随访时,骨特异性碱性磷酸酶(P = 0.03)和脱氧吡啶啉(P = 0.02)水平较低,并且主要是在12个月的骨活检中诊断出低营业额(P = 0.04)。在12个月的骨活检中低周转骨状态是CAC进展的唯一独立预测因子(P = 0.04;β系数= 4.5; 95%CI,1.04至19.39)。根据骨骼组织学检查,最初具有高周转率(n = 5)的非进步者其骨形成率随后降低(P = 0.03),而最初具有低周转率(n = 7)的非进步者其骨形成率随后提高(P = 0.003)和类骨质的体积(P = 0.001)。局限性:人口相对较少,没有严重甲状旁腺功能亢进的患者,观察期短。结论:小骨小梁骨量减少与CAC的发展有关,而骨转换的改善与高和低周转性骨病患者的CAC降低有关。因为CAC与心血管疾病的死亡率有关,所以骨异常可能构成血液透析患者的可改变的死亡危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号